Gland Pharma shares in focus after subsidiary Cenexi gets 11 observations from French regulator

Gland Pharma shares will be in focus on Thursday after the company announced that its material subsidiary, Cenexi, received 11 observations from France’s drug regulator, Agence nationale de sécurité du médicament et des produits de santé (ANSM), following a Good Manufacturing Practices (GMP) inspection at its Fontenay manufacturing facility.

In a stock exchange filing, Gland Pharma stated:

“The ANSM, France, has issued its final report citing 11 observations pursuant to the GMP inspection of Cenexi’s Fontenay manufacturing facility conducted between December 9 and December 19, 2024.”

In response, Cenexi has submitted a Corrective and Preventive Action (CAPA) plan, outlining measures to be implemented over a 3- to 12-month period, depending on the nature of each observation. The plan has been accepted by ANSM.

Also Read: MRF snatches India's highest-priced stock crown back from Elcid Investments

The company clarified that the observations will not impact manufacturing operations at the Fontenay site. Gland Pharma added that Cenexi is committed to resolving the issues in coordination with the French regulator and will continue to update stock exchanges on further developments.

Also Read: These 10 Nifty microcap stocks can rally 70-200% in the next 12 months

Gland Pharma Share Price Target and Performance

According to Trendlyne, the average target price for Gland Pharma is Rs 1,678, implying a potential upside of 3% from current levels. Of the 12 analysts tracking the stock, the consensus rating is ‘Hold’.

On Wednesday, Gland Pharma shares closed 1.88% higher at Rs 1,623.7 on the BSE, while the Sensex gained 0.32%. The stock has rallied 16% in the last one month but remains down 43% over the past three years. The company’s market capitalisation stands at Rs 26,751 crore.

Also Read: Ola Electric, Kalyan Jewellers among 10 firms where promoters pledge increased in Q4

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)